LEUVEN, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Board of Directors has nominated Emmanuèle Attout to be its new Independent non-executive director. Mrs. Attout will join the Audit Committee of the Company.
Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers. She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.
Dr Staf Van Reet, Chairman of ThromboGenics' Board of Directors, said: "We are delighted to welcome Emmanuèle to the ThromboGenics' board as a non-executive director. Her broad business and financial experience, will be extremely valuable to our Board and Audit Committee as we work to execute the standalone strategy we announced in mid-2014."
Commenting on her appointment, Mrs. Attout said: "I am very pleased to be joining the ThromboGenics Board. I have been impressed by the clear strategy that the Company has outlined to build a profitable business focused on providing innovative medicines for the treatment of a number of important vitreo-retinal diseases and I am looking forward to contributing to its successful execution."
Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32
Citigate Dewe Rogerson
David Dible/Malcolm Robertson
Tel: +44 20 7282 2867
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.
ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.
About JETREA ® (ocriplasmin)
JETREA® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA® is indicated for the treatment of symptomatic VMA. In Europe, JETREA® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. JETREA® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
JETREA® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.